Actively Recruiting
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Led by Fuzhou General Hospital · Updated on 2024-02-07
93
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)
CONDITIONS
Official Title
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed localized esophageal squamous cell carcinoma (ESCC) suitable for chemoradiotherapy, including stage II-IVA inoperable ESCC
- Age between 18 and 70 years, any gender
- ECOG performance status score of 0 or 1
- Presence of measurable or non-measurable lesions according to RECIST 1.1
- Adequate organ and bone marrow function with specific blood count and biochemistry levels
- Expected survival time longer than 6 months
- Fertile participants must agree to use medically approved contraception during treatment and for 3 months after last treatment
- Voluntary participation with signed informed consent form
You will not qualify if you...
- History of fistula caused by primary tumor invasion
- Clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage within 2 weeks before randomization
- Known intolerance or resistance to chemotherapy drugs used in this study
- Previous antitumor therapy for ESCC including immunotherapy, radiotherapy, targeted therapy, ablation, or other systemic/local treatments
- Active or history of autoimmune disease that may relapse, or history of allogeneic organ or hematopoietic stem cell transplantation
- History of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases including pulmonary fibrosis and acute lung disease
- Severe chronic or active infections requiring systemic antimicrobial, antifungal, or antiviral therapy prior to enrollment
- Known HIV infection
- Other malignancies within the past 5 years except certain skin and in situ carcinomas
- Received live vaccine within 28 days before enrollment
- Currently participating in another therapeutic clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ye zai sheng
Fuzhou, Fujian, China, 350500
Actively Recruiting
Research Team
F
Fu zhi chao, Doctor of Medicine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here